You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
遠大醫藥(00512.HK):STC3141治療重症新冠IIa期臨牀試驗完成入組給藥
阿思達克 12-14 17:54
遠大醫藥(00512.HK)公佈,附屬Grand Medical Pty Ltd正在開發、用於重症感染領域的全球創新藥物STC3141,日前在歐洲順利完成用於治療重症新冠病毒病IIa期臨牀試驗的全部患者入組,並順利完成受試患者72小時的持續靜脈給藥,觀察期爲用藥後30天,臨牀研究報告預計將在未來6個月內完成。 遠大醫藥表示,重症抗感染領域爲集團核心戰略領域之一,STC3141爲全新作用機制的全球創新產品,除歐洲開展的用於治療重症COVID-19感染患者的IIa期臨牀研究外,已於去年5月在澳洲獲批開展用於治療膿毒症的Ib期臨牀研究,並於去年12月完成首例患者給藥。 目前該項目在中國、澳洲、比利時、英國、波蘭三大洲五個國家,在膿毒症、急性呼吸窘迫綜合症(ARDS)、重症COVID-19感染、COVID-19感染引發的ARDS四個適應症上獲批六個臨牀批件,
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account